Company Profile

Skyran Biologics Inc
Profile last edited on: 10/31/2019      CAGE: 7XLK6      UEI: MMFAJMXZVCM3

Business Identifier: Treating diabetic retinopathy without intraocular injections
Year Founded
----
First Award
2018
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3711 Market Street Suite 800
Harrisburg, PA 17112
   (717) 531-7475
   N/A
   skyranbio.com
Location: Single
Congr. District: 10
County: Dauphin

Public Profile

Anchored in research undertaken by Skyran Biologics Inc principals at Penn State Collee of Medicine, the firm is addressing use of eye-drops - versus intralocular injections - for those suffering from diabetic retinopathy. Within 20 years of a Type 1 Diabetes diagnosis, almost all patients will have damage to the retina of the eye potentially leading to blindness with some 60% of patients diagnosed with Type 2 Diabetes over that period also having some form of Diabetic Retinopathy. Overall this represents some 8M Americans. Typically, treatment involves monthly jcetion directly into the eye. However, current therapies cannot be used in the early stages of the disease and in many patients, the traetments fail. Preliminay data from the work of the principals of Skyran Biologics suggest that their rproprietary PEDF derived peptides could be a platform therapeutic for other ophthalmic degenerative diseases.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2023 2 NIH $1,284,558
Project Title: A Novel PEDF Peptide Mimetic for Diabetic Retinopathy
0 1 NIH $149,664
Project Title: Epigenetic Modifiers to treat Photoreceptor Degenerations

Key People / Management

  Matthew Handel -- Former President

  Joyce Tombran-Tink -- Professor, Department of Neural and Behavioral Sciences

  Ji-Ye Wei

Company News

There are no news available.